Abstract Antibodies are effective therapeutics because of their specificity in binding to an antigen and ability to activate an immune response through Fc effector functions like antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) by engaging with immune cells like NK cells and macrophage. However, traditional methods for characterizing these interactions are highly variable and labor-intensive. We developed a suite of luminescent assays for characterizing antibody effector functions for robust, streamlined measurement across antibody development: Lumit® Binding Immunoassays, Fc Effector Reporter Bioassays for ADCC/ADCP, and HiBiT Target Cell Killing Bioassays using MoA-qualified primary cells. We demonstrate application to anti-CD20 biosimilar antibodies, showing concordant rank order from binding to functional killing studies. These rapid, high-throughput assays support comparability, stability, and lot-release decisions. Citation Format: Julia K. Gilden, Denise Garvin, Kristin Riching, Brock F. Binkowski, Richard Moravec, Pete Stecha, Rod Flemming, Becky Godat, Kai Hillman, Marjeta Urh, Mei Cong, Jamison Grailer, . Binding to bridging: Complete suite of FcγR assay tools accelerates antibody therapeutic development abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1652.
Gilden et al. (Fri,) studied this question.